ALNY Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -143.55%. Alnylam Pharmaceuticals's return on equity of -- beat BridgeBio Pharma's return on equity of --.

Alnylam Pharmaceuticals has a consensus price target of $320.56, signalling upside risk potential of 27.64%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 72.02%. Given that BridgeBio Pharma has higher upside potential than Alnylam Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.75x versus 50.67x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 24.92%. Alnylam Pharmaceuticals's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 9.62%.

Alnylam Pharmaceuticals has a consensus price target of $320.56, signalling upside risk potential of 27.64%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.02 which suggests that it could grow by 63.13%. Given that Biomarin Pharmaceutical has higher upside potential than Alnylam Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.75x versus 3.94x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 21.63%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

Alnylam Pharmaceuticals has a consensus price target of $320.56, signalling upside risk potential of 27.64%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Pfizer has higher upside potential than Alnylam Pharmaceuticals, analysts believe Pfizer is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Pfizer's net income of $3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.75x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 26.7%. Alnylam Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Alnylam Pharmaceuticals has a consensus price target of $320.56, signalling upside risk potential of 27.64%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 51.6%. Given that Regeneron Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.75x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.